Cabozantinib (Compound)

Synonyms:Cabozantinib, 849217-68-1, XL184, Cometriq, XL-184, BMS-907351, XL 184, BMS 907351, XL-184 free base, Cabozantinib (XL184, BMS-907351), Cabozantinib [USAN], CHEBI:72317, BMS907351, 1C39JW444G, BMS-907351 FREE BASE, MFCD20926324, Cabozantinib (USAN), N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE, XL-184 (Cabozantinib,BMS907351), Cabometyx (TN), Cometriq (TN), 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide, 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-, N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, XL184 cpd, Cabozantinib [USAN:INN], Carbozantinib, UNII-1C39JW444G, 1,1-CYCLOPROPANEDICARBOXAMIDE, N'-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N-(4-FLUOROPHENYL)-, XL184 free base, Cabozantinib (free base), CABOZANTINIB [MI], CABOZANTINIB [INN], CABOZANTINIB [VANDF], CABOZANTINIB [WHO-DD], SCHEMBL360795, GTPL5887, Cabozantinib (BMS-907351), CHEMBL2105717, DTXSID10233968, EX-A075, XL184 free base - Cabozantinib, BCPP000308, HMS3654G06, XL-184 free base (Cabozantinib), BCP02591, 849217-68-1 (free base), BDBM50021574, NSC761068, NSC800066, s1119, AKOS025142112, BCP9000470, CCG-264678, CS-0278, DB08875, NSC-761068, NSC-800066, SB20062, XL-184,Cabozantinib, BMS-907351, NCGC00263164-01, NCGC00263164-14, NCGC00263164-17, 1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-, AC-25082, AS-16277, HY-13016, N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide, SY097158, DB-023624, FT-0664184, SW218093-3, D10062, AB01565831_02, Q795057, SR-01000941569, J-523016, SR-01000941569-1, BRD-K51544265-001-01-8, 1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-, 1,1-CYCLOPROPANEDICARBOXAMIDE, N-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)-, cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, cyclopropane-1,1-dicarboxylic acid[4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4 fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide, N-[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]-N inverted exclamation mark -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Pubchem:PUBCHEM:25102847
Id:d8633630-0df6-5886-b8f5-20b2c2883700
Description:nan

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Cabozantinib's neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Cabozantinib.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Cabozantinib.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.